Key Steps in Validating Targeted Protein Degraders
Choose excellence, choose WuXi Biology – your reliable partner in Targeted Protein Degradation (TPD) drug discovery. Since 2016, we have developed comprehensive discovery platforms capable of investigating the complete TPD functional cycle, from binary and ternary complex formation to protein ubiquitination and degradation.
Our broad and deep expertise spans diverse TPD modalities, including PROTACs®, molecular glues, LYTACs, DUBTACs, PHICS, and DACs. Our seamless partnership with WuXi Chemistry enables us to deliver all-encompassing solutions that leverage chemistry, structural biology, target validation, in vitro pharmacology, in vivo evaluation, and biomarker analysis.
Related Content
Antibody-targeted therapies—including antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), and degrader-antibody conjugates (DACs)—are reshaping precision medicine by enabling highly selective delivery...
VIEW RESOURCEDNA-encoded library (DEL) technology has been recognized as a major screening method, offering unique advantages through its ability to provide...
VIEW RESOURCE
